Rtw Investments Adds $8M in Ocugen, Inc. ($OCGN)

RTW Investments has taken a new position in Ocugen, Inc. (NasdaqCM: OCGN), according to its most recent 13F filing with the SEC. The fund acquired 6,666,666 shares, valued at about $8.07 million, marking a fresh investment in the biopharmaceutical company as of the reporting period.

What Changed in RTW Investments' Ocugen Position

RTW Investments' move into Ocugen represents a new position with 6.67 million shares. This initial buy suggests a significant investment in the biotechnology firm, with the shares valued at approximately $8.07 million at the time of the filing.

Other Institutional Activity in Ocugen

Several other institutional investors have also been active in Ocugen. Vanguard Capital Management LLC added 13,804,111 shares, resulting in a total of 13,804,111 shares worth around $24.99 million. Millennium Management LLC increased its holdings by 8,330,775 shares, bringing its total to 13,727,192 shares valued at about $24.85 million. State Street Corp grew its position by 5,691,453 shares, ending with 9,670,191 shares worth approximately $17.50 million. Marshall Wace, LLP added 5,521,394 shares, reaching a total of 8,052,350 shares valued at $14.57 million. BlackRock, Inc. increased its stake by 2,748,435 shares, holding 7,304,979 shares valued at about $13.22 million.

Ocugen, Inc. Stock Snapshot

Shares of Ocugen, Inc. (NasdaqCM: OCGN) recently traded around $1.21. The company has a market capitalization of approximately $409.6 million. Ocugen's stock has a 52-week range between $0.903 and $2.725, with a 50-day moving average of $1.55 and a 200-day moving average of $1.53. The company's forward P/E ratio is not meaningful due to its lack of profitability, and it has a beta of 2.208. Ocugen's current ratio is 1.862, and its debt-to-equity ratio stands at 573.575.

Recent Earnings

Ocugen reported revenue of $4.47 million, reflecting a modest growth of 3.5%. The company's net margin is currently 0.0%, and its return on equity (ROE) is a negative 6.6%. The next earnings report is scheduled for July 30, 2026.

Insider Buying and Selling at Ocugen, Inc.

Recent insider activity at Ocugen includes notable purchases by CEO Shankar Musunuri, who acquired 3,123,201 shares on January 2, 2026. Additionally, Chief Accounting Officer Ramesh Ramachandran purchased 207,300 shares on the same day. On April 1, 2026, insider Zhang Junge bought 194,134 shares at an average price of $0.7948.

Analysts Set New Price Targets

On May 27, 2026, Canaccord Genuity maintained its buy rating for Ocugen with a price target of $11. Earlier in March, HC Wainwright & Co. also maintained a buy rating with a target of $10, while Oppenheimer initiated coverage with a buy rating and a $10 target. The consensus among seven analysts is a buy rating, with a mean price target of $11.43.

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company headquartered in Malvern, Pennsylvania. It focuses on developing gene and cell therapies, biologics, and vaccines. The company is working on treatments for retinal diseases and other conditions, including a COVID-19 vaccine. Ocugen collaborates with organizations such as the National Institute of Allergy and Infectious Diseases and CanSino Biologics Inc.

Bottom Line

RTW Investments' new stake in Ocugen, Inc. highlights the fund's interest in the biotechnology sector. Investors often track 13F filings to gauge institutional confidence in a company's prospects. However, these filings reflect past positions and may not represent current holdings.